A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors

Chen, Shiyun; Guo, Shiyuan; Gou, Miaomiao; Pan, Yuting; Fan, Moli; Zhang, Nan; Tan, Zhao-Li; Dai, Guanghai

doi:10.3389/fonc.2022.951985

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the risk of mortality is significantly increased in patients with PDAC who experience a substantial alteration in NLR after two doses of ICIs [147]. Furthermore, the outcome of PDAC patients treated with PD-1 inhibitors is associated with the combined indicators of NLR and LADH [148]. However, the critical value of the NLR as a predictor of PC immunotherapy has not been universally recognized.…”

Section: Prognostic Value After Pc Immunotherapymentioning

confidence: 99%

Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy

Wu,

Mao,

Jiang

et al. 2024

Immunology

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a highly malignant tumour of the digestive system with poor therapeutic response and low survival rates. Immunotherapy has rapidly developed in recent years and has achieved significant outcomes in numerous malignant neoplasms. However, responses to immunotherapy in PC are rare, and the immunosuppressive and desmoplastic tumour microenvironment (TME) significantly hinders their efficacy in PC. Tumour‐associated neutrophils (TANs) play a crucial role in the PC microenvironment and exert a profound influence on PC immunotherapy by establishing a robust stromal shelter and restraining immune cells to assist PC cells in immune escape, which may subvert the current status of PC immunotherapy. The present review aims to offer a comprehensive summary of the latest progress in understanding the involvement of TANs in PC desmoplastic and immunosuppressive functions and to emphasise the potential therapeutic implications of focusing on TANs in the immunotherapy of this deleterious disease. Finally, we provide an outlook for the future use of TANs in PC immunotherapy.

show abstract

Section: Prognostic Value After Pc Immunotherapymentioning

confidence: 99%

Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy

Wu,

Mao,

Jiang

et al. 2024

Immunology

View full text Add to dashboard Cite

show abstract

“…Patients with PDAC who experience a substantial alteration in NLR following two doses of immune checkpoint blockade are at an increased likelihood of mortality [138]. Furthermore, the outcome in patients with PDAC treated with PD-1 inhibitors is associated with the combined indicators of NLR and LADH [139]. However, NLR, which predicts PC immunotherapy results, has not obtained a recognized critical value currently.…”

Section: Blocking the Immunosuppression-related Targetsmentioning

confidence: 99%

Tumor-associated neutrophils: potential therapeutic targets in pancreatic cancer immunotherapy

Wu,

Mao,

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Pancreatic cancer (PC), a highly malignant tumor of the digestive system with poor therapeutic response and low survival rates. In recent years, immunotherapy have developed rapidly and achieved substantial results in many malignant neoplasms. However, responses to immunotherapy in PC are rare and its immunosuppressive and desmoplastic tumor microenvironment (TME) composes an important impediment to their efficacy in PC. Tumor-associated neutrophils (TANs) play a crucial role in the PC microenvironment, exerting a profound influence on PC immunotherapy through establishing a robust stromal shelter and restraining immune cells to assist PC cells in immune escape, which may subvert the current situation of immunotherapy for PC. The purpose of this review is to offer a thorough summary of the latest progress in comprehending the involvement of TANs in PC desmoplastic and immunosuppressive functions, as well as to emphasize the potential therapeutic consequences of focusing on TANs in the immunotherapy of this destructive ailment. Last but not least, we have provided an outlook for the future of TANs in PC immunotherapy.

show abstract

Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review

Guo,

Pan,

Wan

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Although numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), the prognostic value of the LIPI in a pancancer setting remains unclear. Methods A comprehensive search was conducted until July 2023 across the PubMed, Embase, Web of Science, and Cochrane Library databases to identify relevant studies evaluating the prognostic value of the LIPI in cancer patients treated with ICIs. The outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). We described and compared the pooled outcomes by stratifying the patients based on different groupings of LIPI (good vs. intermediate [0 vs. 1], good vs. poor [0 vs. 2], and good vs. intermediate / poor [0 vs. 1 + 2]). Results A total of 9959 patients in 35 studies were included. A higher score of LIPI was associated with impaired OS. The pooled HRs were 1.69 (95% CI: 1.55–1.85, p < 0.001; 0 vs. 1), 3.03 (95% CI: 2.53–3.63, p < 0.001; 0 vs. 2), and 2.38 (95% CI: 1.97–2.88, p < 0.001; 0 vs. 1 + 2). A higher LIPI score was associated with shorter PFS. The pooled HRs were 1.41 (95% CI: 1.31–1.52, p < 0.001; 0 vs. 1), 2.23 (95% CI: 1.87–2.66, p < 0.001; 0 vs. 2), and 1.65 (95% CI: 1.46–1.86, p < 0.001; 0 vs. 1 + 2). Similarly, a higher LIPI score was associated with a lower ORR. The pooled ORs were 0.63 (95% CI: 0.54–0.75, p < 0.001; 0 vs. 1) and 0.38 (95% CI: 0.29–0.50, p < 0.001; 0 vs. 2). A higher LIPI score was associated with a lower DCR. The pooled ORs were 0.47 (95% CI: 0.35–0.61, p < 0.001; 0 vs. 1) and 0.19 (95% CI: 0.12–0.30, p < 0.001; 0 vs. 2). Conclusion In patients with NSCLC or other solid tumours, the lung immune prognostic index could robustly stratify the clinical outcomes into three groups among the patients who receive ICIs. LIPI is a low-cost, simple, accessible, and accurate prognostic tool in a pancancer setting and it may contribute to the evaluation of risk stratification in patients treated with ICIs.

show abstract

A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors

Cited by 5 publications

References 30 publications

Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy

Tumour‐associated neutrophils: Potential therapeutic targets in pancreatic cancer immunotherapy

Tumor-associated neutrophils: potential therapeutic targets in pancreatic cancer immunotherapy

Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review

Contact Info

Product

Resources

About